“Alexa, process this data for me” 3 ways the AI evolution is redefining how we collect market insights
In this article first published in PME magazine, Marketing Manager Harrison Gaiger outlines the three ways AI is redefining how we collect market insights.
Amazon’s digital voice assistant Alexa is much more than just a convenient tool for setting reminders, streaming music and controlling the lights in our homes. It is a very real application of Artificial Intelligence (AI), a technology that has fast become an integral part of our daily lives. With all of the hype surrounding the more attention-grabbing applications of AI such as self-driving cars and super human-like robots - which most commentators say will be commonplace soon, it can often be difficult to appreciate just how much AI affects what we’re doing right now. We have all become so accustomed to AI without even realising it e.g., the autocorrect function on our smartphones and the automatic tagging of friends in our Facebook photos are both powered by AI.
Launching novel oncology therapies in Asia: Identifying and communicating value
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success.
Market access in Brazil: All eyes on Spinraza
Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.
Living with Atopic Dermatitis: Effects beyond the skin’s surface
Head of Living With, Mariel Metcalfe, discusses the nature of Atopic Dermatitis and some key findings from a recent study conducted in Europe
Earlier this year, we published the report “Living with Atopic Dermatitis (AD) EU”, based on primary market research, which reveals key insights and unmet needs from the AD adult and paediatric patient perspective and treatment journey. In December 2017, we published a US report, which is also available to purchase.
Engaging patient advocacy groups: The key to conducting effective rare disease research
This article, published by Pharma Times September 2019, outlines why market researchers should reach out to patient advocacy groups when conducting rare disease research.
Until recently, the size of the market for specific rare diseases had made it difficult for pharmaceutical companies to justify research and development costs. The introduction of regulatory benefits such as longer market exclusivity, breakthrough designations, reduced fees and tax incentives have encouraged more investment. Nevertheless, where funding has been allocated for rare diseases, the scarcity and geographical dispersal of patients can make it difficult to conduct effective market research. Identifying and recruiting respondents is one of the core challenges when conducting research in this space.